Nephrology

Back to articles

Low-dose gentamicin supplement to endocarditis therapy poses adverse event risk

KEY POINT

An analysis of safety data from 236 patients showed that the addition of short-term, low-dose gentamicin therapy to antistaphylococcal penicillins or vancomycin for the management of Staphylococcus aureus bacteremia and native valve endocarditis increases the risk of renal adverse events.